A Phase 2 interventional study of Rabeprazole and Rabeprazole in Functional Dyspepsia, sponsored by Eisai Co., Ltd.. Completed at 46 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2013-12-24.
Sponsored by Eisai Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the efficacy and safety of rabeprazole compared to placebo in Japanese subjects with Functional Dyspepsia.
372 studies on the registry are indexed under Dyspepsia; 66 are open to participants now.
This study's enrollment of 338 is above the median of 89 across 302 interventional studies indexed under Dyspepsia.
Browse Dyspepsia studies →Eisai Co., Ltd. is the lead sponsor of 152 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
-Participants diagnosed as Functional Dyspepsia according to Rome III criteria.
Exclusion criteria:
Drug: Rabeprazole
Drug: Rabeprazole
Drug: Rabeprazole
Drug: Placebo
Rabeprazole 10 mg tablet taken orally once daily after breakfast for 8 weeks.
Also known as: E3810
Rabeprazole 20 mg tablet taken orally once daily after breakfast for 8 weeks.
Also known as: E3810
Rabeprazole 40 mg tablet taken orally once daily after breakfast for 8 weeks.
Also known as: E3810
Rabeprazole Placebo tablet taken orally once daily after breakfast for 8 weeks.
Also known as: E3810
Rate of Complete Dyspepsia Symptom Relief
The rate of complete dyspepsia symptom relief according to the Dyspepsia Symptom Questionnaire (DSQ) was defined as a score of 1 for all four major dyspeptic symptoms at week 8 and according to the diary defined as all four dyspepsia symptoms recorded absent during the 7 days prior to week 8. Values presented as percentage of participants.
Time frame: Up to 8 Weeks (including 7 days prior)
Rate of Satisfactory Symptom Relief
The rate of satisfactory symptom relief according to the DSQ defined as scores of \<= 2 for all four major dyspepsia symptoms at week 8 and the diary recordings defined as a frequency of \<= 1 day for all four major dyspepsia symptoms during the 7 days before week 8. Lastly, treatment success according to the participants' impression questionnaire where participants answered "yes" or "no" when asked if given the choice, whether they would want to continue to take the study drug after clinical trial completion. Values presented as percentage of participants.
Time frame: Up to 8 Weeks (including 7 days prior)
This study was recruited at 66 centers in Japan during the period of 21-April-2010 to 12-Aug-2011.
| Milestone | Rabeprazole 10 mg | Rabeprazole 20 mg | Rabeprazole 40 mg | Placebo |
|---|---|---|---|---|
| Started | 84 | 85 | 84 | 85 |
| Completed | 81 | 81 | 81 | 83 |
| Not completed | 3 | 4 | 3 | 2 |
| Withdrew: Withdrawal by subject | 2 | 3 | 3 | 1 |
| Withdrew: Physician decision | 1 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 |
The rate of complete dyspepsia symptom relief according to the Dyspepsia Symptom Questionnaire (DSQ) was defined as a score of 1 for all four major dyspeptic symptoms at week 8 and according to the diary defined as all four dyspepsia symptoms recorded absent during the 7 days prior to week 8. Values presented as percentage of participants.
| Percentage of Participants | Rabeprazole 10 mg | Rabeprazole 20 mg | Rabeprazole 40 mg | Placebo |
|---|---|---|---|---|
| DSQ (n= 76, n= 75, n= 74, n= 78) | 22.4 | 29.3 | 27.0 | 17.9 |
| Diary Recordings (n= 77, n= 76, n=74, n=80) | 22.1 | 28.9 | 27.0 | 17.5 |
The rate of satisfactory symptom relief according to the DSQ defined as scores of \<= 2 for all four major dyspepsia symptoms at week 8 and the diary recordings defined as a frequency of \<= 1 day for all four major dyspepsia symptoms during the 7 days before week 8. Lastly, treatment success according to the participants' impression questionnaire where participants answered "yes" or "no" when asked if given the choice, whether they would want to continue to take the study drug after clinical trial completion. Values presented as percentage of participants.
| Percentage of participants | Rabeprazole 10 mg | Rabeprazole 20 mg | Rabeprazole 40 mg | Placebo |
|---|---|---|---|---|
| DSQ (n=76, n=75, n=74, n=78) | 42.1 | 45.3 | 39.2 | 28.2 |
| Diary Recordings (n=77, n=76, n=74, n=80) | 37.7 | 48.7 | 39.2 | 30.0 |
| Treatment Success (n=76, n=75, n=74, n=78) | 72.4 | 85.3 | 64.9 | 59.0 |
Collected over Up to 8 weeks. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rabeprazole 10 mg | — | 0/85 (0%) | 28/85 (32.9%) |
| Rabeprazole 20 mg | — | 1/85 (1.2%) | 20/85 (23.5%) |
| Rabeprazole 40 mg | — | 1/83 (1.2%) | 31/83 (37.3%) |
| Placebo | — | 1/85 (1.2%) | 22/85 (25.9%) |
| Event | Rabeprazole 10 mg | Rabeprazole 20 mg | Rabeprazole 40 mg | Placebo |
|---|---|---|---|---|
| Abdominal DistensionGastrointestinal disorders | 0/85 | 1/85 | 1/83 | 1/85 |
| Event | Rabeprazole 10 mg | Rabeprazole 20 mg | Rabeprazole 40 mg | Placebo |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 10/85 | 7/85 | 15/83 | 4/85 |
| Back PainMusculoskeletal and connective tissue disorders | 3/85 | 0/85 | 0/83 | 4/85 |
| StomatitisGastrointestinal disorders | 0/85 | 0/85 | 3/83 | 1/85 |
| DiarrhoeaGastrointestinal disorders | 3/85 | 3/85 | 2/83 | 2/85 |
| GastroenteritisInfections and infestations | 0/85 | 3/85 | 0/83 | 0/85 |
| PharyngitisInfections and infestations | 0/85 | 1/85 | 1/83 | 3/85 |
| Blood Triglycerides IncreasedInvestigations | 3/85 | 0/85 | 0/83 | 2/85 |
| HeadacheNervous system disorders | 3/85 | 3/85 | 1/83 | 0/85 |
| EnterocolitisGastrointestinal disorders | 0/85 | 0/85 | 2/83 | 0/85 |
| Gastroenteritis ViralInfections and infestations | 0/85 | 0/85 | 2/83 | 0/85 |
Per Protocol Set (PPS): was defined as those participants who complied with the study protocol. N= 338 participants were enrolled at study start. However, a total of 307 participants were included in PPS for efficacy evaluation.
| Age, Continuous(years) | Rabeprazole 10 mg | Rabeprazole 20 mg | Rabeprazole 40 mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 46.9 ± 14.9 | 50.2 ± 16.5 | 46.4 ± 14.8 | 45.8 ± 15.5 | 47.3 ± 15.5 |
| Sex: Female, Male(Participants) | Rabeprazole 10 mg | Rabeprazole 20 mg | Rabeprazole 40 mg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 43 | 40 | 47 | 44 | 174 |
| Male | 34 | 36 | 27 | 36 | 133 |
The record gives a start of Apr 2010, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2013, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rabeprazole